These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7897410)

  • 21. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disability profile of multiple sclerosis in New Zealand.
    Alla S; Pearson JF; Taylor BV; Miller DH; Clarke G; Richardson A; Willoughby E; Abernethy DA; Sabel CE; Mason DF
    J Clin Neurosci; 2016 Jun; 28():97-101. PubMed ID: 26765754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.
    Hohol MJ; Orav EJ; Weiner HL
    Mult Scler; 1999 Oct; 5(5):349-54. PubMed ID: 10516779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
    Rabadi MH; Vincent AS
    Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; De Keyser J
    Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.
    Thompson AJ; Kermode AG; MacManus DG; Kendall BE; Kingsley DP; Moseley IF; McDonald WI
    BMJ; 1990 Mar; 300(6725):631-4. PubMed ID: 2138923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?
    Moroso A; Deloire MS; Ruet A; Ouallet JC; Casey R; Brochet B
    J Neurol Sci; 2015 Jul; 354(1-2):51-5. PubMed ID: 25977107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
    Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
    Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
    Cho JY; Hong KS; Kim HJ; Kim SH; Min JH; Kim NH; Ahn SW; Park MS; An JY; Kim BJ; Kim W
    Mult Scler; 2014 Aug; 20(9):1217-23. PubMed ID: 24399825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K; Walsh C; Antonelli G; Hutchinson M
    Mult Scler; 2007 Apr; 13(3):336-42. PubMed ID: 17439902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.
    Bernitsas E; Bao F; Seraji-Bozorgzad N; Chorostecki J; Santiago C; Tselis A; Caon C; Zak I; Millis S; Khan O
    Mult Scler Relat Disord; 2015 Jan; 4(1):47-51. PubMed ID: 25787052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.
    Skoog B; Runmarker B; Winblad S; Ekholm S; Andersen O
    Brain; 2012 Mar; 135(Pt 3):900-11. PubMed ID: 22366800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X
    Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.
    Confavreux C; Vukusic S; Adeleine P
    Brain; 2003 Apr; 126(Pt 4):770-82. PubMed ID: 12615637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validity of patient-derived disability and clinical data in multiple sclerosis.
    Ingram G; Colley E; Ben-Shlomo Y; Cossburn M; Hirst CL; Pickersgill TP; Robertson NP
    Mult Scler; 2010 Apr; 16(4):472-9. PubMed ID: 20150395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.
    Guillemin F; Baumann C; Epstein J; Kerschen P; Garot T; Mathey G; Debouverie M;
    Neuroepidemiology; 2017; 48(3-4):179-187. PubMed ID: 28793296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis.
    Binquet C; Quantin C; Le Teuff G; Pagliano JF; Abrahamowicz M; Moreau T
    Neuroepidemiology; 2006; 27(1):45-54. PubMed ID: 16825794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.